You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRibostamycin
Accession NumberDB03615  (EXPT02786)
TypeSmall Molecule
GroupsApproved
DescriptionA broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus. Ribostamycin, along with other aminoglycosides with the DOS (2-deoxystreptamine) subunit, is an important broad-spectrum antibiotic with important use against human immunodeficiency virus and is considered a critically important antimicrobial by the World Health Organization.
Structure
Thumb
Synonyms
5-Amino-2-Aminomethyl-6-[4,6-Diamino-2-(3,4-Dihydroxy-5-Hydroxymethyl-Tetrahydro-Furan-2-Yloxy)-3-Hydroxy-Cyclohexyloxy]-Tetrahydro-Pyran-3,4-Diol
Ribastamin
RIO
Vistamycin
Xylostacin
Xylostasin
External Identifiers
  • Antibiotic SF 733
  • SF-733
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2Q5JOU7T53
CAS number25546-65-0
WeightAverage: 454.4727
Monoisotopic: 454.227493328
Chemical FormulaC17H34N4O10
InChI KeyNSKGQURZWSPSBC-NLZFXWNVSA-N
InChI
InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13+,14-,15-,16+,17-/m0/s1
IUPAC Name
(2S,3R,4S,5S,6R)-5-amino-2-(aminomethyl)-6-{[(1S,2S,3R,4S,6R)-4,6-diamino-2-{[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[[email protected]](O[[email protected]]2[[email protected]](N)C[[email protected]](N)[C@@H](O)[C@@H]2O[C@@H]2O[C@@H](CO)[[email protected]](O)[[email protected]]2O)[C@@H](N)[[email protected]](O)[[email protected]]1O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionAminoglycosides work by binding to the bacterial 30S ribosomal subunit (some work by binding to the 50S subunit), inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, leaving the bacterium unable to synthesize proteins vital to its growth. However, their exact mechanism of action is not fully known.
TargetKindPharmacological actionActionsOrganismUniProt ID
Protein disulfide-isomeraseProteinunknownNot AvailableHumanP07237 details
30S ribosomal protein S12ProteinunknownNot AvailableEscherichia coli (strain K12)P0A7S3 details
Aminoglycoside N(6')-acetyltransferase type 1ProteinunknownNot AvailableSalmonella enteritidisQ9R381 details
Aminoglycoside 2'-N-acetyltransferaseProteinunknownNot AvailableMycobacterium tuberculosisP0A5N0 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Ribostamycin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Alendronic acidRibostamycin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
AmpicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Ribostamycin.Investigational
ApremilastApremilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Atracurium besylateRibostamycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Ribostamycin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
Botulinum Toxin Type ARibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BRibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Ribostamycin.Approved
CarbenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinRibostamycin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateRibostamycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Ribostamycin.Approved
ClodronateRibostamycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateRibostamycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineRibostamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
DecamethoniumRibostamycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Ribostamycin.Approved
Domoic AcidRibostamycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideRibostamycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Etidronic acidRibostamycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Ribostamycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.Approved, Vet Approved
Gallamine TriethiodideRibostamycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
IbandronateRibostamycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MecamylamineRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Ribostamycin can be decreased when it is combined with Meticillin.Approved
MetocurineRibostamycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideRibostamycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumRibostamycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
NeosaxitoxinRibostamycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Ribostamycin.Approved
OxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
PamidronateRibostamycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumRibostamycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ribostamycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
PipecuroniumRibostamycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Ribostamycin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
PyrantelRibostamycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumRibostamycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental, Investigational
RisedronateRibostamycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumRibostamycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
SuccinylcholineRibostamycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Ribostamycin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Ribostamycin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateRibostamycin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateRibostamycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Ribostamycin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateRibostamycin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.Approved
TranilastTranilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TubocurarineRibostamycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Ribostamycin.Approved
VecuroniumRibostamycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidRibostamycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, “1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof.” U.S. Patent US4008218, issued February, 1974.

US4008218
General ReferencesNot Available
External Links
ATC CodesJ01GB10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point193.5 °CPhysProp
pKa7.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility88.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.4ChemAxon
logS-0.71ALOGPS
pKa (Strongest Acidic)12.19ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area262.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.17 m3·mol-1ChemAxon
Polarizability44.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,5-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Monosaccharide
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attached to the cell. May therefore cause structural modifications of exofacial proteins. Inside the cell, seems to form/rearrange disulfide bonds of nascent proteins. At high concentrations, functions as a...
Gene Name:
P4HB
Uniprot ID:
P07237
Molecular Weight:
57115.795 Da
References
  1. Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M: Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72. [PubMed:11741285 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
Kind
Protein
Organism
Salmonella enteritidis
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Catalyzes the transfer of an acetyl group from acetyl-CoA to the 6'-amino group of aminoglycoside molecules conferring resistance to antibiotics containing the purpurosamine ring including amikacin, tobramycin, dibekacin and ribostamycin. Able to acetylate eukaryotic histone proteins.
Gene Name:
Not Available
Uniprot ID:
Q9R381
Molecular Weight:
16361.42 Da
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Involved in N-acetyltransferase activity
Specific Function:
Catalyzes the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides. It confers resistance to aminoglycosides
Gene Name:
aac
Uniprot ID:
P0A5N0
Molecular Weight:
20038.0 Da

Enzymes

Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Involved in N-acetyltransferase activity
Specific Function:
Catalyzes the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides. It confers resistance to aminoglycosides
Gene Name:
aac
Uniprot ID:
P0A5N0
Molecular Weight:
20038.0 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23